Safety and Efficacy of Hepatic Artery Embolization in Treating Solitary Fibrous Tumor Metastatic to the Liver
Joint Authors
Jarnagin, William
Solomon, Stephen B.
Brody, Lynn A.
Brown, Karen T.
Tap, William D.
Ziv, Etay
Erinjeri, Joseph P.
Yarmohammadi, Hooman
Boas, Franz E.
Velayati, Sara
Covey, Anne M.
Kingham, Peter T.
Getrajdman, George I.
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-09-03
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
The aim of this study was to evaluate safety and survival following hepatic artery embolization (HAE) for metastatic solitary fibrous tumor (SFT) in the liver.
All patients with SFT metastatic to liver treated with HAE were retrospectively analyzed.
Tumor response was evaluated using mRECIST.
Objective response, overall survival (OS), and progression-free survival (PFS) were evaluated using Kaplan–Meier and multivariate Cox proportional hazard ratio.
Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.
Twelve patients (6 males and 6 females, mean age: 42.5 ± 13 years; 24–65) were treated with 33 embolizations.
Anatomical sites of origin for SFT were the head and neck (n = 6; 50%), pelvis (n = 2), pleura (n = 2), retroperitoneal (n = 1), and thigh (n = 1).
The median follow-up from first HAE was 4.5 years (3–7.9).
84% of the patients showed objective response [42% complete response (CR) plus 42% partial response (PR)] to HAE by mRECIST (95% CI, 60–99%).
Patients with CR to HAE had significantly higher OS compared to others (p<0.02).
The postembolization median OS was 4 years (95% CI, 2.3–5.2), and mean PFS, for intra- or extrahepatic progression of disease, was 6 months (95%, CI, 3.2–7.1).
One patient developed pneumonia/sepsis and died 27 days postembolization, possibly not directly related to embolization.
No grade III or IV adverse events were identified in the remaining patients.
In conclusion, HAE for metastatic liver SFT is a relatively safe treatment option with high response rate and should be considered as a treatment option for metastatic liver SFT.
In our cohort of patients with metastatic SFT to the liver, we observed a median OS of 4 years following HAE.
Further studies are needed to confirm the efficacy of HAE.
American Psychological Association (APA)
Velayati, Sara& Erinjeri, Joseph P.& Brody, Lynn A.& Ziv, Etay& Boas, Franz E.& Brown, Karen T.…[et al.]. 2019. Safety and Efficacy of Hepatic Artery Embolization in Treating Solitary Fibrous Tumor Metastatic to the Liver. Complexity،Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1207626
Modern Language Association (MLA)
Velayati, Sara…[et al.]. Safety and Efficacy of Hepatic Artery Embolization in Treating Solitary Fibrous Tumor Metastatic to the Liver. Complexity No. 2019 (2019), pp.1-6.
https://search.emarefa.net/detail/BIM-1207626
American Medical Association (AMA)
Velayati, Sara& Erinjeri, Joseph P.& Brody, Lynn A.& Ziv, Etay& Boas, Franz E.& Brown, Karen T.…[et al.]. Safety and Efficacy of Hepatic Artery Embolization in Treating Solitary Fibrous Tumor Metastatic to the Liver. Complexity. 2019. Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1207626
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1207626